Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The B-cell receptor (BCR) specific for tetanus toxoid epitopes is a specialized membrane-bound immunoglobulin complex found on the surface of B lymphocytes. It plays a central role in the adaptive immune response by recognizing and binding to specific antigenic determinants (epitopes) of the tetanus toxoid, which is the inactivated form of the neurotoxin tetanospasmin produced by Clostridium tetani (Source: NIH StatPearls, Creative Diagnostics). Upon antigen binding, the BCR initiates a signal transduction cascade—typically involving the CD79a and CD79b subunits—that triggers B-cell activation, proliferation, and differentiation into antibody-secreting plasma cells and long-lived memory B cells (Source: NIH PubMed, NIH StatPearls). This interaction is the primary mechanism of action for tetanus vaccines, such as DTaP and Tdap, which aim to establish a pool of memory B cells capable of a rapid and robust response upon future exposure to the tetanus toxin (Source: Wikipedia, Mayo Clinic). In clinical and research settings, these receptors are used as critical biomarkers to evaluate vaccine efficacy and to study the persistence of immunological memory in various patient populations (Source: NIH PubMed, ResearchGate). For instance, the frequency and affinity of TT-specific BCRs can indicate the success of a booster immunization or the extent of immune depletion following treatments like Rituximab (Source: ResearchGate, NIH PubMed). Furthermore, the identification of specific linear B-cell epitopes within the tetanus toxin has allowed for the development of high-resolution diagnostic assays and the design of novel conjugate vaccines (Source: NIH PubMed, Universiteit Leiden). Understanding the interaction between these receptors and their epitopes is essential for optimizing vaccine schedules and developing targeted immunotherapies that leverage existing anti-tetanus immunity (Source: Universiteit Leiden, ResearchGate).
The tetanus toxoid antigen binds to the B-cell receptor, inducing receptor clustering and activation of the CD79a/CD79b signaling complex, which triggers B-cell proliferation and differentiation into plasma cells and memory B cells.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tetanus toxoid-specific B-cell receptor (TT-BCR).